MedPacto announced on Jan. 2 that it has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for the combination therapy of Vactosertib and Pembrolizumab (commercially known as Keytruda).This clinical trial targets patients with previo
An increasing number of orphan drugs developed by South Korean companies are entering the U.S. market, where more incentives are given to such drugs than in South Korea.Examples of such drugs recently approved by the U.S. FDA include MedPacto’s Vactosertib, HLB Therapeutics’ RGN-259, Hanmi Pharmaceu
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and sehunjang@shinhan.com, respectively. – Ed. Biotech stocks on a losing streak since 2021Biotech stocks have continued on a losing streak in 1H22. Investor appetite for growth stocks has declined in t
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Preparing to present interim results from phase Ib clinical trial of Vactosertib-FOLFOX combo therapy in pancreatic cancer at ASCO 2022MedPacto, on May 27, ann
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
MedPacto, Inc., a genome-based drug discovery and clinical-stage biotechnology company, announced on Feb. 14 that it has entered into a clinical trial agreement with University Hospitals Cleveland Medical Center in the United States to pursue an investigator-initiated clinical trial in patients with
MedPacto, Inc., a genome-based drug discovery and clinical-stage biotechnology company, announced on Feb. 11 that it has partnered with HITS, an artificial intelligence (AI) drug discovery company, to co-develop new drugs.Under the terms of the agreement, the two companies will practice drug develop
Medpacto, a new drug developer that recently stirred up controversy due to two patient deaths during a clinical trial and the rejection of a change in the clinical trial plan, announced on Jan. 14 that its CEO Kim Sung-jin bought 24,780 treasury shares.According to the disclosure, the price per shar
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. At the 2021 ASCO, Oscotec’s Lazertinib was presented as achieving an ORR of 90% in IHC-positive biomarkers for Tagrisso-resistant patients. MedPacto showed off superior data (compared to global pharm
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Clinical results of combo therapy for colorectal cancer to be announced at ASCO2021; conditional approval looks possibleMedPacto will announce the results of P
The authors are analysts of Shinhan Investment Corp. They can be reached at shawn1225@shinhan.com and jhwon@shinhan.com, respectively. – Ed. Pharma/bio tend to outperform broader markets from the start of the yearPharmaceutical/bio stocks usually outperform the broader markets from the start of the
The authors are analysts of NH Investment & Securities. They can be reached at william.ku@nhqv.com and weihan@nhqv.com, respectively. – Ed. 1. Confident towards domestic bio sector’s mid/long-term growth potentialDomestic bio sector: 20-year-long new drug development historyKorea’s first domesticall
Anti-cancer drugs developed in Korea are receiving love calls from global pharmaceutical and biotechnology companies.According to the pharmaceutical industry on October 9, overseas pharmaceutical companies are seeking cooperation with Korean companies to increase the effectiveness of their drugs by